Tahir Siddique et al. 2025. Efficacy and Safety of Once-Weekly Semaglutide versus Tirzepatide in Type 2 Diabetes: A 24-Week Randomized Clinical Trial. Journal of Health, Wellness and Community Research. 3, 1 (Mar. 2025), 1–8. DOI:https://doi.org/10.61919/qxt0b644.